Indian Journal of Neurosurgery 2016; 05(01): 022-024
DOI: 10.1055/s-0036-1572373
Case Report
Neurological Surgeons' Society of India

Hereditary Afibrinogenemia: Rare Bleeding Disorder Presenting with Spontaneous Extradural Hematoma – A Brief Review

Guru Dutta Satyarthee
1   Department of Neurosurgery, All India Institute of Medical Science, New Delhi, India
,
Ashok K. Mahapatra
2   Department of Neurosurgery, All India Institute of Medical Science, Bhuvneshwar, India
› Author Affiliations
Further Information

Publication History

18 June 2015

18 November 2015

Publication Date:
25 February 2016 (online)

Abstract

Afibrinogenemia is considered as rare hereditary bleeding disorder with autosomal recessive genetic transmission, caused by mutations of any one out of the three genes located on chromosome 4, responsible for coding of three polypeptide chains, constituents of fibrinogen. Clinical manifestation include spontaneous bleeding, bleeding following trivial trauma, and excessive profuse bleeding during major trauma constitute commoner manifestations. Replacement therapy remains main treatment of bleeding episodes using plasma-derived fibrinogen concentrate. However, fresh frozen plasma and cryoprecipitate, recombinant fibrinogens are considered as alternative treatment options. The authors reports a 2-year-old girl, diagnosed as case of hypofibrinogenemia since birth and was under regular supervision of pediatric hematologist, getting fresh frozen plasma replacement therapy every third weeks, developed extradural hematoma and was managed surgically with good outcome.

 
  • References

  • 1 Acharya SS, Coughlin A, Dimichele DM ; North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004; 2 (2) 248-256
  • 2 Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104 (5) 1243-1252
  • 3 Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci PM. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999; 107 (1) 204-206
  • 4 Asselta R, Duga S, Tenchini ML. The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost 2006; 4 (10) 2115-2129
  • 5 Acharya SS, Dimichele DM. Rare inherited disorders of fibrinogen. Haemophilia 2008; 14 (6) 1151-1158
  • 6 Castaman G. Prophylaxis of bleeding episodes and surgical interventions in patients with rare inherited coagulation disorders. Blood Transfus 2008; 6 (Suppl. 02) s39-s44
  • 7 Dupuy E, Soria C, Molho P , et al. Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in vivo circulating thrombin. Thromb Res 2001; 102 (3) 211-219
  • 8 Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia 2008; 14 (4) 671-684
  • 9 Bolton-Maggs PH, Perry DJ, Chalmers EA , et al. The rare coagulation disorders—review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10 (5) 593-628